{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:03:55Z","timestamp":1790402635624,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002641","name":"Konkuk University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002641","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.bbrc.2020.04.121","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:33:18Z","timestamp":1588293198000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy"],"prefix":"10.1016","volume":"527","author":[{"given":"Sang Hyung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Tae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heejin","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ui Beom","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Seok","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2020.04.121_bib1","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J."},{"key":"10.1016\/j.bbrc.2020.04.121_bib2","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","article-title":"Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation","volume":"192","author":"Freeman","year":"2000","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.bbrc.2020.04.121_bib3","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/85330","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bbrc.2020.04.121_bib4","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/nm863","article-title":"Blockade of B7-H1 improves myeloid dendritic cell\u2013mediated antitumor immunity","volume":"9","author":"Curiel","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbrc.2020.04.121_bib5","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1158\/0008-5472.1089.65.3","article-title":"Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity","volume":"65","author":"Hirano","year":"2005","journal-title":"Canc. Res."},{"key":"10.1016\/j.bbrc.2020.04.121_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbrc.2020.04.121_bib7","first-page":"36","volume":"3","author":"Khoja","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2020.04.121_bib8","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2020.04.121_bib9","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.bbrc.2020.04.121_bib10","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.bbrc.2020.04.121_bib11","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s40265-018-1012-5","article-title":"Cemiplimab: first global approval","volume":"78","author":"Markham","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2020.04.121_bib12","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2020.04.121_bib13","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s00262-018-2160-x","article-title":"The binding of an anti-PD-1 antibody to Fc\u03b3R\u0399 has a profound impact on its biological functions","volume":"67","author":"Zhang","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbrc.2020.04.121_bib14","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1038\/ncomms13354","article-title":"Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy","volume":"7","author":"Lee","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.04.121_bib15","doi-asserted-by":"crossref","first-page":"5532","DOI":"10.1038\/s41598-017-06002-8","article-title":"Molecular mechanism of PD-1\/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2020.04.121_bib16","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.3390\/molecules24061190","article-title":"Molecular interactions of antibody drugs targeting PD-1, PD-L1, and CTLA-4 in immuno-oncology","volume":"24","author":"Lee","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.bbrc.2020.04.121_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/cr.2016.77","article-title":"Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab","volume":"27","author":"Na","year":"2017","journal-title":"Cell Res."},{"key":"10.1016\/j.bbrc.2020.04.121_bib18","doi-asserted-by":"crossref","first-page":"14369","DOI":"10.1038\/ncomms14369","article-title":"An unexpected N-terminal loop in PD-1 dominates binding by nivolumab","volume":"8","author":"Tan","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bbrc.2020.04.121_bib19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(97)76066-X","article-title":"Processing of X-ray diffraction data collected in oscillation mode","volume":"276","author":"Otwinowski","year":"1997","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bbrc.2020.04.121_bib20","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J.\u00a0Appl. Crystallogr."},{"key":"10.1016\/j.bbrc.2020.04.121_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2020.04.121_bib22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1107\/S0907444909052925","article-title":"PHENIX\u00a0: a comprehensive Python-based system for macromolecular structure solution","volume":"66","author":"Adams","year":"2010","journal-title":"Acta Crystallogr. Sect. D Biol. Crystallogr."},{"key":"10.1016\/j.bbrc.2020.04.121_bib23","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1073\/pnas.0712278105","article-title":"The PD-1\/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors","volume":"105","author":"Lin","year":"2008","journal-title":"Proc. Natl. Acad. Sci. Unit. States Am."},{"key":"10.1016\/j.bbrc.2020.04.121_bib24","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/j.str.2015.09.010","article-title":"Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1","volume":"23","author":"Zak","year":"2015","journal-title":"Structure"},{"key":"10.1016\/j.bbrc.2020.04.121_bib25","doi-asserted-by":"crossref","first-page":"11771","DOI":"10.1074\/jbc.M112.448126","article-title":"Structure and interactions of the human programmed cell death 1 receptor","volume":"288","author":"Cheng","year":"2013","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2020.04.121_bib26","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229206","article-title":"Assessing the binding properties of the anti-PD-1 antibody landscape using label-free biosensors","volume":"15","author":"Brown","year":"2020","journal-title":"PLoS One"}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20308615?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X20308615?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:52:35Z","timestamp":1757764355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X20308615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S0006291X20308615"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.121","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2020.04.121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}